TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06168942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: Laminar Left Atrial Appendage Closure System
Description: Participants will be treated with the Laminar Left Atrial Appendage Closure System.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: WATCHMAN / Amulet
Description: Participants will be treated with a WATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder.
Study: NCT06312826

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal US
Description: The acquired images included B-mode images of the left hepatic lobe through transverse and longitudinal scans including images of the umbilical portion of the left portal vein, and images of the right hepatic lobe through subcostal and intercostal scans including images of the right hepatic dome, right portal vein, and right hepatic vein with additional images of the confluence of both portal vein and three hepatic veins. When a liver observation was seen, additional images were taken, and its diameter was measured on both transverse and longitudinal planes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AMRI
Description: The study subjects receive intravenous injection of gadoxetic acid (0.025 mmol/kg, Primovist; Bayer, Berlin, Germany) in the waiting room and then proceed to the examination room for MRI testing 15-20 minutes later. The MRI examination is conducted using a 3T MRI machine, and the MRI protocol consists of T2-weighted imaging, diffusion-weighted imaging (b value of 0, 50, and 500 s/mm2), and hepatobiliary phase imaging.
Study: NCT06113328

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-6194
Description: MK-6194 administered subcutaneously (SC)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-6194
Description: MK-6194 administered subcutaneously (SC)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-6194
Description: MK-6194 administered subcutaneously (SC)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-6194
Description: MK-6194 administered subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator to MK-6194 administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator to MK-6194 administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator to MK-6194 administered SC
Study: NCT06442618

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shockwave Treatment (Group A)
Description: Each session involved a 1:1 ratio of patient to physiatrist. The treatment modality was explained to the patient preliminarily, and before each session, the patients were clinically evaluated and the location of pain was identified.; so patients were asked to assume a comfortable position, and treatment with focal ESWTs was started as per the ISMST protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutraceutical Supplementation (Group B)
Description: Participants in Group B performed home therapy with nutraceutical supplementation containing: hyaluronic acid (200 mg), collagen (5,000 mg), manganese (10 mg) and vitamin C (250 mg), daily for 30 days. Patients were advised to shake the compound, before taking, and to store it at room temperature not exceeding 25 °C, in a cool, dry place, away from light and heat sources. The compound is also free of gluten and lactose, so it can be safely administered.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined Treatment (Group C)
Description: Participants in group C were invited to come to our department\&#39;s outpatient clinics to perform treatment with focal ESWT; they had one session every six days for a total of 5 sessions lasting about 20 minutes each. Patients in this group took also additional nutraceutical therapy; they took a daily supplemental treatment of hyaluronic acid, collagen, vitamin C and manganese for 30 days.
Study: NCT05604625

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Van-Beek activator and a headgear
Description: 12 patients will receive Van-Beek activator and a headgear

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Andresen activator
Description: 12 patients will receive Andresen activator.
Study: NCT06524674

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydration Multiplier + Energy
Description: Participants will be administered one oral serving of an oral rehydration solution containing caffeine and l-theanine

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydration Multiplier + Sleep
Description: Participants will be administered one oral serving of an oral rehydration solution containing melatonin and l-theanine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Energy Comp
Description: Participants will be administered one oral serving of a comparator oral rehydration solution containing caffeine and l-theanine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sleep Comp
Description: Participants will be administered one oral serving of a comparator oral rehydration solution containing melatonin and l-theanine
Study: NCT05557331

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PIMPmyHospital (mobile app)
Description: After the implementation of the app, data will be collected prospectively over a 6-month period of use. This will include the times (HH:MM:SS) when the results issued by the central laboratory are made available on caregivers' mobile app and access times (as well as concurrent or preferred access times on the conventional computerized workstations should this occur).
Study: NCT05262907

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transthoracic Echocardiogram or Cardiac MRI
Description: Non-invasive imaging of the heart to evaluate structure and function.
Study: NCT06191367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercises
Description: Aerobic Exercises
Study: NCT05262907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventripoint Echocardiogram
Description: Non-invasive ultrasound of the heart to evaluate structure and function through 3D imaging.
Study: NCT05613738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01
Description: All patients were intravenous injected with single dose 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01
Description: All patients were intravenous injected with single dose 1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01
Description: All patients were intravenous injected with single dose 2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
Study: NCT06435104

Intervention type: OTHER
Group type: OTHER
Intervention: neoadjuvant chemotherapy
Description: The neoadjuvant chemotherapy plan will be selected according to the recommendations of the NCCN guidelines and the Chinese CSCO guidelines for early breast cancer.The neoadjuvant chemotherapy plans include:AC-T(HP),TCb(HP),AC-TCb, in which A represents anthracycline, C represents cyclophosphamide, T represents taxane, Cb represents carboplatin, H represents trastuzumab, and P represents pertuzumab.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy
Description: The neoadjuvant chemotherapy plan will be selected according to the recommendations of the NCCN guidelines and the Chinese CSCO guidelines for early breast cancer.The neoadjuvant chemotherapy plans include:AC-T(HP),TCb(HP),AC-TCb, in which A represents anthracycline, C represents cyclophosphamide, T represents taxane, Cb represents carboplatin, H represents trastuzumab, and P represents pertuzumab.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aromatherapy
Description: Patients will inhale essential oils during the neoadjuvant chemotherapy courses.
Study: NCT05129943

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active distraction
Description: The subject receives the injection of local anesthesia while playing a game on a mobile phone mounted on the VR device using a PS4 controller.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: passive distraction
Description: The subject receives the injection of local anesthesia while watching a cartoon on a mobile phone mounted on the VR device.
Study: NCT05204810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anticoagulation strategy
Description: For each session of this cross-over study, a different anticoagulation therapy is used: either 1 dose of anticoagulant or 2 doses of anticoagulant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anticoagulation strategy
Description: For each session of this cross-over study, a different anticoagulation therapy is used: either 1 dose of anticoagulant or 2 doses of anticoagulant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: During the study sessions, blood sampling is performed from the arterial blood line at different time points (5min, 60min, 240min and at the dialysis end)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: During the study sessions, blood sampling is performed from the arterial blood line at different time points (5min, 60min, 240min and at the dialysis end)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scanning of hemodialyzer with micro-computed tomography
Description: After the study sessions, the used hemodialyzers are scanned using a gold standard micro computed tomography technique.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scanning of hemodialyzer with micro-computed tomography
Description: After the study sessions, the used hemodialyzers are scanned using a gold standard micro computed tomography technique.
Study: NCT05161299

Intervention type: PROCEDURE
Intervention: Surgery (across all specialities)
Description: Surgery performed by a surgeon in an operating theatre during the patient inclusion period
Study: NCT04954599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-506
Description: CP-506 is a hypoxia-activated DNA alkylating agent specifically designed to have a bystander effect, aqueous solubility, oral bioavailability, and no off-mechanism activation by the human aerobic reductase AKR1C3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-506
Description: CP-506 is a hypoxia-activated DNA alkylating agent specifically designed to have a bystander effect, aqueous solubility, oral bioavailability, and no off-mechanism activation by the human aerobic reductase AKR1C3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-506
Description: CP-506 is a hypoxia-activated DNA alkylating agent specifically designed to have a bystander effect, aqueous solubility, oral bioavailability, and no off-mechanism activation by the human aerobic reductase AKR1C3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-506
Description: CP-506 is a hypoxia-activated DNA alkylating agent specifically designed to have a bystander effect, aqueous solubility, oral bioavailability, and no off-mechanism activation by the human aerobic reductase AKR1C3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-506
Description: CP-506 is a hypoxia-activated DNA alkylating agent specifically designed to have a bystander effect, aqueous solubility, oral bioavailability, and no off-mechanism activation by the human aerobic reductase AKR1C3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-506
Description: CP-506 is a hypoxia-activated DNA alkylating agent specifically designed to have a bystander effect, aqueous solubility, oral bioavailability, and no off-mechanism activation by the human aerobic reductase AKR1C3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Antineoplastic agent, ATC Code: LO1X A02

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Antineoplastic agent, ATC Code: LO1X A02

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitor
Description: Drug that blocks immune checkpoint proteins: PD-1, PD-L1, CTLA-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitor
Description: Drug that blocks immune checkpoint proteins: PD-1, PD-L1, CTLA-4
Study: NCT06217757

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy
Description: The LDRT deals with primary tumour in a 15 Gy of 5fractions over five days, starting from Day 1 in the first cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be administered intravenously at a dose of 100 mg/m\^2 on Days 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered as intravenous infusion at a dose of 25 mg/m\^2 on Days 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugemalimab
Description: Sugemalimab will be administered by intravenous infusion at a dose of 1200mg on Day 1 of each 21-day cycle for a maximum of 2 years or progressive disease or intolerable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib will be administered orally at a dose of 150mg qod Day 1,3,5,7 or 150 mg qd/150 mg bid/300mg in the morning and 150mg in the evening/300 mg bid on Day 1-7 of each 21-day cycle for a maximum of 2 years or progressive disease or intolerable toxicity.
Study: NCT05565729

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY3471851
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3471851
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3471851
Description: Administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Description: Administered orally.
Study: NCT05648162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical acupuncture
Description: Electrical acupuncture (2Hz, 150 μs) once daily (five times a week), for 20 minutes each session, totaling 20 sessions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Electrical acupuncture (no electricity) once daily (five times a week), for 20 minutes each session, totaling 20 sessions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS (1mA) once daily (five times a week), for 20 minutes each session, totaling 20 sessions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham tDCS
Description: tDCS (no electricity) once daily (five times a week), for 20 minutes each session, totaling 20 sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NDT-Bobath Rehabilitation
Description: NDT-Bobath Rehabilitation once daily (five times a week), for 30 minutes each session, totaling 20 sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NDT-Bobath Rehabilitation
Description: NDT-Bobath Rehabilitation once daily (five times a week), for 30 minutes each session, totaling 20 sessions.
Study: NCT05907382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMKX003002 will be administered orally
Description: oral once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMKX003002 will be administered orally
Description: oral once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMKX003002 will be administered orally
Description: oral once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in Cohorts 1 to 5
Description: oral once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in 2 Cohorts
Description: oral once
Study: NCT05960825

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: injectable platelet rich fibrin versus microosteoperforation
Description: injectable platelet rich fibrin which is second product of blood versus microosteoperforation which is surgical procedure

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: injectable platelet rich fibrin versus microosteoperforation
Description: injectable platelet rich fibrin which is second product of blood versus microosteoperforation which is surgical procedure
Study: NCT05695781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BRM421 Ophthalmic Solution
Description: A topical drop of BRM421 ophthalmic solution.
Study: NCT06191367

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Incentive Spirometer Device
Description: is a handheld medical device used to help patients improve the functioning of their lungs. By training patients to take slow and deep breaths, this simplified spirometer facilitates lung expansion and strengthening. Patients inhale through a mouthpiece, which causes a piston inside the device to rise. This visual feedback helps them monitor their inspiratory effort. Incentive spirometers are commonly used after surgery or other illnesses to prevent pulmonary complications.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Chest Physiotherapy
Description: 1. Breathing exercise.~2. Postural drainage.~3. Percussion.~4. Coughing.~5. Vibration.
Study: NCT05695781

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: A topical drop of vehicle (minus active) ophthalmic solution.
Study: NCT05374564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (18F)Flutemetamol
Description: 18F-Flutemetamol binds to β-amyloid plaques and the F-18 isotope produces a positron signal that is detected by a PET scanner. Multiple recent studies have shown that thioflavin-analogue tracers such as 18F-flutemetamol may be able to fulfill the unmet need of elucidating the presence of amyloid deposition in the heart. Because it binds to the beta-pleated motif of the amyloid fibril due to their similarity to the thioflavin structure, 18F-Flutemetamol could potentially be used to image cardiac amyloidosis (CA)
Study: NCT06191367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Chest Physiotherapy
Description: 1. Breathing exercise.~2. Postural drainage.~3. Percussion.~4. Coughing.~5. Vibration.
Study: NCT06175325

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Trans-radial embolisation of haemorrhoids
Description: Once patients have provided informed consent to participate, an assessment of symptom severity will be obtained during the initial visit using the a standardised set of 4 validated scoring systems used in research of haemorrhoidal disease. These include the French bleeding score (FBS), Goligher classification of internal haemorrhoids (GS), quality of life score (QoL) and Visual analogue score for pain (VAS). Routine blood tests will be taken. During the procedure, routine observations will be recorded on the paper CRF. The data collected on the paper CRF will be entered onto the electronic CRF.~The Transarterial fluoroscopically guided superior rectal artery embolization procedure will be performed on all participants. It is a day case procedure performed under local anaesthetic.
Study: NCT06299384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LyssnCrisis
Description: LyssnCrisis is an AI-based coding and feedback tool for implementation in crisis counseling settings, training counselors (call-takers) in suicide risk assessment skills.
Study: NCT06152146

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shockwave Therapy
Description: Each therapy session will last about 20 minutes, during which 1,440 shockwaves will be applied to the penis via the left and right crus (shaft near the base)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SHAM shockwave therapy
Description: Each therapy session, lasting about 20 minutes, will deliver 1440 SHAM shockwave therapy applied to the penis via the left and right crus (shaft near the base)
Study: NCT05390567

Intervention type: BEHAVIORAL
Intervention: Participant Choice of HPV Self-Test
Description: Opportunity for participants to complete the HPV self-test in a non-clinical setting to be returned via a mailer or courier servie.
Study: NCT06191367

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Chest Physiotherapy
Description: 1. Breathing exercise.~2. Postural drainage.~3. Percussion.~4. Coughing.~5. Vibration.
Study: NCT05073575

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: After local anesthesia, an access flap will be prepared. Scaling and root planning will be performed combining the use of metal curettes and power-driven instrumentation by means of ultrasonic scaler.~Hyaluronic acid gel will be applied to exposed roots surface, followed by a tension-free primary closure of the surgery wound by means of 5-0 monofilament (polypropylene) non-resorbable suturing material.
Study: NCT05390567

Intervention type: BEHAVIORAL
Intervention: Survey: Participant cancer history and cervical cancer prevention/screening knowledge
Description: Asking women to respond to questions about their cancer history and knowledge of cervical cancer prevention and screening.

Intervention type: BEHAVIORAL
Intervention: Survey: Participant cancer history and cervical cancer prevention/screening knowledge
Description: Asking women to respond to questions about their cancer history and knowledge of cervical cancer prevention and screening.

Intervention type: BEHAVIORAL
Intervention: Participant Choice of Standard of Care in-clinic Pap-test
Description: Participant choice of cervical cancer screening method with either a SOC in-clinic pap test or HPV self-test
Study: NCT06573450

Intervention type: OTHER
Intervention: questionnaire survey
Description: subjects fill out questionnaires

Intervention type: OTHER
Intervention: questionnaire survey
Description: subjects fill out questionnaires

Intervention type: OTHER
Intervention: questionnaire survey
Description: subjects fill out questionnaires

Intervention type: OTHER
Intervention: questionnaire survey
Description: subjects fill out questionnaires
Study: NCT05094531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary prevention programm
Description: This programm aims to adress three dimensions : (i) biophysiology (flexibility of the autonomic nervous system), (ii) psychology (flexibility of coping strategies, sens of mission) and (iii) the social (stigmatization, seeking health care).